Gewichtsmanagement 2 min read

Retatrutide

META-TITLE: [TODO: Retatrutide — Triple Agonist Research Profile | Brand]
META-DESC: [TODO: In-depth retatrutide research profile covering GLP-1/GIP/glucagon triple agonism, Phase 2 data, dosing, and safety.]

[TODO] Hook — retatrutide as the first GLP-1/GIP/glucagon triple receptor agonist, Eli Lilly development, why it is generating significant research interest

[IMAGE: Molecular structure or 3D render of Retatrutide peptide]

What is Retatrutide?

[TODO] Full name — Retatrutide (LY3437943), investigational triple agonist peptide
[TODO] Developer — Eli Lilly and Company
[TODO] Classification — GLP-1/GIP/glucagon receptor tri-agonist
[TODO] Molecular format — single peptide chain, fatty acid acylation for extended half-life
[TODO] Current status — Phase 2 completed, Phase 3 ongoing

Mechanism of Action

[IMAGE: Diagram showing the three receptor pathways — GLP-1R (appetite), GIPR (insulin), GCGR (energy expenditure)]

[TODO] GLP-1 receptor — appetite suppression, gastric emptying delay, insulin secretion
[TODO] GIP receptor — enhanced insulin sensitivity, potential adipose tissue effects
[TODO] Glucagon receptor — hepatic glucose output, energy expenditure increase, lipid metabolism
[TODO] Synergy — triple agonism additive/synergistic effects vs mono/dual agonists
[TODO] Half-life — ~6 days, enabling once-weekly administration in studies

Research Highlights

[TODO] Phase 2 trial (2023) — up to 24.2% body weight reduction at 48 weeks (12mg dose)
[TODO] Dose-response — 1mg, 4mg, 8mg, 12mg escalation cohorts
[TODO] Metabolic markers — HbA1c, fasting glucose, lipid panel improvements
[TODO] Liver fat reduction — significant hepatic steatosis reduction observed
[TODO] Comparison context — numerically higher weight reduction than semaglutide/tirzepatide Phase 2 data

Dosing Protocols (Research Context)

[TODO] Escalation — start low (1mg), titrate over weeks to minimize GI side effects
[TODO] Maintenance dose range — 4-12mg once weekly (subcutaneous)
[TODO] Administration — subcutaneous injection, abdomen/thigh
[TODO] Storage — lyophilized form, reconstitution with BAC water, refrigerate

Safety & Considerations

[TODO] GI tolerability — nausea, diarrhea, vomiting (most common, dose-dependent)
[TODO] Heart rate — mild increase observed in some cohorts
[TODO] Thyroid — standard GLP-1 class C-cell concern (rodent thyroid tumors)
[TODO] Limited long-term data — Phase 2 only, awaiting Phase 3